Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, and Lung Cancer Research Studies.
Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study.
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
<i>Ex Vivo</i> Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab
Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature
DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers